BCL2 and lymphoma: Sixty-four (45.4%) tumors showed a MYC rearrangement; 29 (20.57%) samples thereof had an additional BCL2 rearrangement (hence belonging to the DHL category); one lymphoma sample revealed translocations in MYC, BCL2, and BCL6 (THL).